JNNP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DEVUYST, G
Right arrow Articles by BOGOUSSLAVSKY, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DEVUYST, G
Right arrow Articles by BOGOUSSLAVSKY, J
J Neurol Neurosurg Psychiatry 1999;67:420-425 ( October )

Editorial

Recent progress in drug treatment for acute stroke

The first 150 words of the full text of this article appear below.

The publication of the positive results of the National Institutes of Neurological Disease and Stroke (NINDS)1 trial of alteplase (a recombinant tissue plasminogen activator) for patients with acute stroke in 1995 and its approval by the US Food and Drug Administration as well as by the American Academy of Neurology and American Heart Association2 3 increased the interest and attention of the medical community for acute stroke treatment. However, the implication of this NINDS Stroke Study and other thrombolytic trials in clinical practice remains extremely controversial and debated. Furthermore, the recent publication of the results from the European Cooperative Acute Stroke Study II (ECASS II)4 will feed the controversy as ECASS II4 results are disappointing and do not confirm the positive results of the NINDS Stroke Study.1 Consequently, what is the more reasonable position concerning thrombolysis by alteplase, and what seems to work has not been established yet beyond reasonable doubt. Numerous . . . [Full text of this article]


This article has been cited by other articles:


Home page
 StrokeHome page
S. I. Savitz, R. Lew, E. Bluhmki, W. Hacke, and M. Fisher
Shift Analysis Versus Dichotomization of the Modified Rankin Scale Outcome Scores in the NINDS and ECASS-II Trials
Stroke, December 1, 2007; 38(12): 3205 - 3212.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
T. Crocco, T. Gullett, S. M. Davis, N. Flores, L. Sauerbeck, E. Jauch, B. Threlkeld, B. Pio, M. Ottaway, A. Pancioli, et al.
Feasibility of Neuroprotective Agent Administration by Prehospital Personnel in an Urban Setting
Stroke, August 1, 2003; 34(8): 1918 - 1922.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
Recommendations for Clinical Trial Evaluation of Acute Stroke Therapies
Stroke, July 1, 2001; 32(7): 1598 - 1606.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1999 by the BMJ Publishing Group Ltd.